TerminatedPhase 4

Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

Stopped: Difficult to enroll subjects

United States33 participantsStarted 2014-03

Plain-language summary

Our hypothesis is that prophylactic administration of 5 days of Octreotide following EMR or ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm.

Who can participate

Age range18 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Duodenal or ampullary adenoma greater than or equal to 10mm Duodenal or ampullary adenoma that is suitable for endoscopic mucosal resection Medically fit for anesthesia, endoscopy, and EMR Able to provide Informed Consent 18 years or older, male and female Exclusion Criteria: Duodenal or ampullary adenoma \<10mm Duodenal or ampullary adenoma that is not suitable for endoscopic mucosal resection Medically unfit for anesthesia, endoscopy, or EMR Unable to provide informed consent Less than 18 years old Allergy to Octreotide

What they're measuring

Post endoscopic mucosal resection bleeding

Timeframe: 3 days

Trial details

NCT IDNCT02032784

SponsorAdventHealth

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-06-28

View on ClinicalTrials.gov More Adenoma trials